Comparative efficacy of tofacitinib vs. adalimumab in RA - metanalysis of 9 RCTs, 24,643 pts finds Tofa signif superior to ADA for ACR20 (RR 1.28), HAQ-DI, VAS, but no difference in adverse events (RR 0.96) or DAS28-CRP improvement https://t.co/5mVY2Qvdms https://t.co/czxnlYHEAl

Ph 2 open label RCT TOFA in RA-ILD 52 wks 39pts 92% AE 8% 3 deaths FVC decline -69 ml No diff between UIP, NSIP or antifibrotic No control group #POS0619 #EULAR2025 @RheumNow https://t.co/3lqEUfObG9

What’s worse for infection in GCA: tail end steroid taper, or a JAK inhibitor? This is exactly SELECT-GCA in the second 6mo. What happened? upa skews better on serious infection, worse on HZ JAKi might have infection risk, but not like steroids. OP0057 #EULAR2025 @RheumNow https://t.co/FigxviOW3e

Early PsA? Treat fast, treat hard. The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 responses vs standard care in a T2T strategy. By 12 months, outcomes were similar, but early SEC needed fewer escalations. Abstract#OP0092 @RheumNow #EULAR2025 https://t.co/cAZTc9eN16

Combination therapies in PsA not so far away: -Case series of 22 patients from large PsA cohort. -Combination therapy in PsA used when difficult to treat skin and msk involvement. -Deucravacitinib was the agent mostly used in combination with bDMARDs. -No major serious adverse https://t.co/YUyvuaJcsE

Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR IL17i + JAKi 10.5 PY = 1 mild infectious stomatitis IL23i + JAKi 3.7 PY = no AE IL-17i + TYK2i 8.5 PY = 2 mild upper respiratory infections IL-23i + TYK2i 8.3 PY = 2 mild URIs, 1 folliculitis TNFi + https://t.co/Qg9HIwuslJ

Can IL-17F signalling be modulated by treatment with TNFi? In PsA pts non responders to previous TNFi, there was increased expression of IL17F-related gene signature. Suggesting a potential mechanism for the consistent level of clinical response observed with BKZ. Abstract https://t.co/D6fvp18UTz

#EULAR2025 Abstr#OP0074 Manufacturing time for CAR-T can be a hindrance. Preliminary study (N=10 #SLE patients) of CD19/BCMA dual-targeting CAR-T developed on the novel FasTCAR-T platform with next-day manufacturing, showed promising efficacy and safety signals @RheumNow https://t.co/bgF04qe9C7

Early intensive therapy in PsA. STAMP RCT in early PsA: •ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC) •MDA at 3mo: 48% vs 25% •PASI90 at 3mo: 60% vs 22% By 12months: outcomes similar, but early secukinumab led to faster control and fewer therapy escalations. https://t.co/TKa5z24NQX